Michael Makris/LinkedIn
Nov 19, 2025, 02:49
Michael Makris: Novo Nordisk has Decided to Discontinue Their Haemophilia A Gene Editing Program
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of RPTH Journal, shared on LinkedIn:
“Novo Nordisk has decided to discontinue their haemophilia A gene editing program.
Novo Nordisk have had concizumab approved recently, and I expect their bispecific Mim8 to be approved soon. I expect this had a major impact on the decision to discontinue the gene editing program.”
Stay updated with Hemostasis Today.
-
Oct 9, 2026, 12:03Heather Case: Bridging Awareness and Action in Women’s Hemophilia Care
-
Oct 9, 2026, 11:58Brandon Luu: Can Iron Deficiency Cause Fatigue Without Anemia?
-
Oct 9, 2026, 11:51Sumaiya Dickens: Marginal Zone B Cells in Transfusion Medicine and Hemophilia A Research
-
Oct 9, 2026, 11:44Ayyappan V Nair: PRP and Rehabilitation – Can It Help Athletes with Partial Rotator Cuff Tears?
-
Oct 9, 2026, 11:29Jigesha Dholakia: Supporting the Hemophilia Community Through the Unite Walk
-
Oct 9, 2026, 11:06Nobles Green: How siRNA Therapy Helps the Body Form Stronger Clots
-
Oct 9, 2026, 10:53Switching From Emicizumab to Denecimig in Hemophilia A – Rare Disease Advisor
-
Oct 9, 2026, 10:40What New U.S. Data Reveal About GT – Glanzmann’s Research Foundation
-
Oct 9, 2026, 10:32Anjali Pandey: The Morphologic Clues to MDS With del(5q)